European regulators green-light a host of new drugs
There was a lineup of important European drug decisions released today. At the top of the list:
European regulators have given a green light to Glaxosmithkline's OTC version of the obesity drug Xenical.
- check out the report from The Scotsman
ALSO: France's Ipsen announced that the CHMP recommended marketing authorization for Increlex. A formal approval will trigger a $20 million milestone payment to Tercica. Release
> European regulators are recommending the use of Sanofi-Aventis' Plavix for stent patients. Report
> Roche's anemia drug Mircera got a thumb's up from European regulators as well. The therapy has been delayed in the U.S. as the FDA ponders the fate of anemia drugs in the face of new safety data. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


